Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen. Issue 4 (26th August 2017)

• Record Type: Journal Article
• Authors: Gane, Edward J.; Shiffman, Mitchell L.; Etzkorn, Kyle; Morelli, Giuseppe; Stedman, Catherine A.M.; Davis, Mitchell N.; Hinestrosa, Federico; Dvory‐Sobol, Hadas; Huang, K.C.; Osinusi, Anu; McNally, John; Brainard, Diana M.; McHutchison, John G.; Thompson, Alex J.; Sulkowski, Mark S.
• Is Part Of: Hepatology. Volume 66:Issue 4(2017)
• Page Start: 1083
• Page End: 1089
• Publication Date: 2017-08-26
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.29256
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract : The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct‐acting antiviral–based therapies remains unclear. In this multicenter, open‐label, phase 2 study, we evaluated the efficacy and safety of a fixed‐dose combination of sofosbuvir‐velpatasvir (400 mg/100 mg) plus weight‐adjusted ribavirin administered for 24 weeks in patients who did not achieve sustained virologic response after prior treatment with direct‐acting antiviral regimens that included the nucleotide analogue nonstructural protein 5B inhibitor sofosbuvir plus the nonstructural protein 5A inhibitor velpatasvir with or without the nonstructural protein 3/4A protease inhibitor voxilaprevir. The primary efficacy endpoint was the proportion of patients achieving sustained virologic response at 12 weeks after the cessation of treatment. In total, 63 of 69 (91%; 95% confidence interval, 82%‐97%) patients achieved sustained virologic response at 12 weeks, including 36 of 37 (97%; 95% confidence interval, 86%‐100%) patients with hepatitis C virus genotype 1 infection, 13 of 14 (93%; 95% confidence interval, 66%‐100%) patients with genotype 2 infection, and 14 of 18 (78%; 95% confidence interval, 52%‐94%) patients with genotype 3 infection. Most adverse events were of mild or moderate severity. The most frequently reported adverse events were fatigue, nausea, headache, insomnia, and rash. One patient (1%) with genotype 1a infection discontinued all study drugs due to an adverse event (irritability). Conclusion: Retreatment of patients who previously failed direct‐acting antiviral–based therapies with sofosbuvir‐velpatasvir plus ribavirin for 24 weeks was well tolerated and effective, particularly those with hepatitis C virus genotype 1 or 2 infection. (Hepatology 2017;66:1083‐1089).